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Abstract
Background: Although the survival benefits of antiretroviral therapy (ART) for the treatment of HIV
infection are well established, the clinical management of HIV disease continues to present major
challenges. There are particular concerns regarding access to appropriate HIV treatment among HIV-
infected injection drug users (IDU).
Methods: In a prospective cohort study of HIV-infected IDU in Vancouver, Canada, we examined initial
ART regimens vis-à-vis the provincial government's therapeutic guidelines at the time ART was initiated.
Briefly, there have been four sets of guidelines: Era 1 (1992 to November 1995; double-drug (dual NRTIs)
ART for patients with a CD4 cell count of 350 or less); Era 2 (December 1995 to May 1996; double-drug
therapy for patients with a CD4+ cell count of 500 or less); Era 3 (June 1996 to June 1997; triple-drug
therapy (dual NRTIs with a PI or NNRTI) for patients who had a plasma viral load of > 100,000 HIV-1
RNA copies/mL; dual therapy with two NRTIs for those with a plasma viral load of 5,000 to 100,000 HIV-
1 RNA copies/mL); Era 4 (since July 1997; universal use of triple drug therapy as first-line treatment).
Results: Between May 1996 and May 2003, 431 HIV-infected individuals were enrolled into the cohort.
By May 31, 2003, 291 (67.5%) individuals had initiated ART. We noted instances of inappropriate
antiretroviral prescription in each guideline era, with 9 (53%) in Era 1, 3 (12%) in Era 2, 22 (28%) in Era 3,
and 23 (15%) in Era 4. Of the 57 subjects who received an inappropriate ART regimen initially, 14 never
received the appropriate therapy; among the remaining 43, the median time to the initiation of a guideline-
appropriate ART regimen was 12 months (inter-quartile range 5 – 20).
Conclusion: The present study identified measurable rates of guideline-inappropriate ART prescription
for patients who were injection drug users. Rates were highest in the era of dual therapy, although high
rates persisted into the triple-therapy era. As therapeutic guidelines continue to evolve, it is critical that
mechanisms be put in place to ensure prescription of ART combinations for IDU that are consistent with
current expert recommendations.
Published: 04 January 2007
Harm Reduction Journal 2007, 4:2 doi:10.1186/1477-7517-4-2
Received: 24 October 2006
Accepted: 04 January 2007
This article is available from: http://www.harmreductionjournal.com/content/4/1/2
© 2007 Wood et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Harm Reduction Journal 2007, 4:2 http://www.harmreductionjournal.com/content/4/1/2
Page 2 of 4
(page number not for citation purposes)
Background
Since the introduction of antiretroviral therapy (ART) in
the mid-1990s, the survival benefits of this treatment for
the management of HIV infection have been well estab-
lished [1-4]. Nevertheless, the clinical management of
HIV disease continues to present major challenges. Per-
sons undergoing treatment for HIV disease must follow a
daily regimen, known as highly active antiretroviral ther-
apy (HAART), consisting of at least three antiretroviral
drugs (i.e., two nucleoside reverse transcriptase inhibitors
[NRTIs] plus a protease inhibitor [PI] or a non-nucleoside
reverse transcriptase inhibitor [NNRTI]), and follow a
scheduled dosing protocol that often involves coordina-
tion of dietary intake [5]. Previous studies have demon-
strated that persons initially prescribed non-HAART
regimens consisting of only one or two antiretroviral
drugs have a lesser virologic response [19, 20], as well as
significantly shorter survival than persons who initiate
therapy with HAART [21, 22].
Since the advent of ART, there have been growing con-
cerns regarding access to HIV treatment among HIV-
infected injection drug users (IDU) [6,7]. Studies have
demonstrated that IDU may be less likely to receive ART,
even in settings where all HIV/AIDS care is provided free
of charge [8]. We have recently shown that in comparison
to non-injection drug users, IDU are more likely to be pre-
scribed non-HAART regimens, even after adjustment for
baseline clinical characteristics [9]. However, a compre-
hensive examination of the prevalence of inappropriate
ART prescription among injection drug users has not pre-
viously been conducted. We therefore examined the rate
of ART in a prospective cohort of HIV-infected injection
drug users and examined the prevalence of ART prescrip-
tions that were inappropriate, given the recommenda-
tions of therapeutic guidelines at the time ART was
initiated.
Methods
The Barriers to Antiretroviral Therapy (BART) cohort, a
prospective study of HIV-infected injection drug users
who have been recruited through self-referral and street
outreach from the Downtown Eastside of Vancouver,
Canada, since May 1996, has been described in detail pre-
viously [6,10]. Briefly, participants complete an inter-
viewer-administered questionnaire, are provided referral
to primary health care and addiction treatment where
available, and are provided a nominal stipend at each
study visit. Ethical approval has been annually provided
by the University of British Columbia's Research Ethics
Board. The BART cohort is unique in that it does not rely
on self-reported use of ART, since endpoints related to the
use of antiretroviral therapy can be accurately ascertained
through a confidential record linkage with the province's
centralized HIV/AIDS monitoring and treatment registry
which includes all patients receiving ART in the province
of British Columbia [6,10,11].
The primary endpoint of interest in the present analysis
was the content of the initial ART regimen, and we were
specifically interested in the rate of antiretroviral therapy
use that was inconsistent with the recommendations of
the province's therapeutic guidelines at the time antiretro-
viral therapy was initiated. The guidelines in the province
of British Columbia have been described in detail previ-
ously [2,12]. Briefly, between 1992 and November 1995
(Era 1), the guidelines made available double-NRTI
antiretroviral therapy for people with a CD4 cell count of
350 or less; between December 1995 and May 1996 (Era
2), double-NRTI therapy was made available to everyone
with a CD4+ cell count of 500 or less; between June 1996
and June 1997 (Era 3), antiretroviral therapy guidelines
based on plasma viral load were used, and individuals
who had a plasma viral load of > 100,000 HIV-1 RNA cop-
ies/mL were offered triple-drug regimens (i.e., HAART),
whereas those with a plasma viral load of 5,000 to
100,000 HIV-1 RNA copies/mL were offered dual NRTI
therapy; and in July 1997 (Era 4), the guidelines univer-
sally recommended the use of HAART as first-line treat-
ment.
Results
Between May 1996 and May 2003, 431 HIV infected indi-
viduals were enrolled into the BART cohort. Antiretroviral
use was subsequently prospectively and retrospectively
examined for these individuals through a confidential
record linkage with the province's centralized HIV/AIDS
treatment program, and it was determined that 291
(67.5%) individuals had initiated antiretroviral therapy
by May 31, 2003. Overall, 19 (6.9%) individuals had to
be excluded from subsequent analyses because baseline
plasma HIV RNA measures and/or baseline CD4 cell
count measures were unavailable.
Among the study sample of 272 individuals, the median
age of these participants was 36 (inter-quartile range: 30 –
42), 118 (43.4%) were female, and 115 (42.3%) reported
being of non-white race. Overall, 17 (6.3%) participants
initiated ART in Era 1, 26 (29.4%) in Era 2, 80 (29.4%) in
Era 3, and 149 (54.8%) in Era 4.
We noted that there were instances of inappropriate
antiretroviral prescription in each era, with 9 (53%) in Era
1, 3 (12%) in Era 2, 22 (28%) in Era 3, and 23 (15%) in
Era 4. In Eras 1 and 2, all inappropriate prescriptions
involved individuals being prescribed mono therapy
when they should have received dual therapy based on
their CD4 cell count. In Era 3, all inappropriate prescrip-
tions involved subjects who should have received triple
therapy based on their plasma HIV RNA but received dualHarm Reduction Journal 2007, 4:2 http://www.harmreductionjournal.com/content/4/1/2
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therapy instead (2 NRTIs in all cases). Finally, in Era 4,
when patients should have received triple therapy, 4
patients received single NNRTI therapy, 3 patients
received single NRTI therapy, 6 patients received dual
therapy with one NRTI and a PI or a NNRTI, and 10
patients received dual NRTI therapy. Overall, of the 57
subjects who received an incorrect ART prescription ini-
tially, 14 never received the correct number of drugs, and
among the remaining 43, the median time to the initia-
tion of a correct ART regimen was 12 months (inter-quar-
tile range 5 – 20). Interestingly, when we compared those
to received appropriate ART to those that received guide-
line-inappropriate ART, we found that no physician or
patient characteristics were associated with receiving inap-
propriate therapy.
Discussion
In the present study, we documented measurable rates of
ART prescription that were inconsistent with the recom-
mendations of the therapeutic guidelines that were in
place at the time that ART was initiated. Our findings may
be explained by the difficulty some physicians may have
had in keeping up with changes in HIV therapeutic guide-
lines and by the fact that inappropriate prescriptions com-
monly resulted from lack of knowledge about the change
in guidelines [9]. In addition, limited access to appropri-
ate ART combinations among persons with a history of
injection drug use may reflect the belief of some physi-
cians that persons with less stable lifestyles may have bet-
ter adherence to a less complex regimen [7,13]. Finally, it
is also possible that concerns regarding possible transmis-
sion of PI- or NNRTI-resistant virus influenced prescribing
decisions [14,15].
With regard to the above, it is noteworthy that a recent
study demonstrated that a substantial proportion of
homeless and marginally housed individuals had good
adherence to antiretroviral therapy including protease
inhibitors, and that resistance to PIs was rare among those
who were non-adherent [25]. Furthermore, it was recently
argued that physicians should not indefinitely withhold
ART from patients who are thought to be poorly adherent
[26], and studies have shown that providers may be poor
judges of adherence [27]. The present study demonstrates
the high rate of inappropriate ART prescription but is lim-
ited in its ability to explain why measurable numbers of
IDU received incorrect HAART regimens. Future studies
should examine physician and patient reasons for select-
ing specific ART regimens. Studies are also needed to
examine ways to ensure physician compliance with thera-
peutic guidelines since it is likely that HIV therapies will
continue to be multi-drug, and that therapeutic guidelines
will continue to evolve rapidly [16]. In our own setting
where HAART delivery is centralized, systems are now in
place to ensure all prescriptions are consistent with cur-
rent therapeutic guidelines.
Conclusion
In the present study, we documented measurable rates of
inappropriate ART prescribing patterns among injection
drug users. Rates were highest in the era of dual therapy,
although high rates persisted into the era of HAART. Since
HIV therapeutic guidelines will likely continue to evolve
as novel agents become available and additional informa-
tion about ART benefits and toxicities arises, it is critical
that mechanisms be put in place to ensure that physicians
are providing ART combinations that are up-to-date with
current knowledge.
Acknowledgements
We would particularly like to thank the BART participants for their willing-
ness to participate in the study. We also thank Caitlin Johnston, Deborah 
Graham, Steve Kain, Peter Vann, Cody Callon, Sidney Crosby, Vanessa 
Volkommer, Aaron Eddie, Trevor Logan, Cristy Power, Daniel Kane, Calvin 
Lai, and Will Small for their administrative assistance. The study was sup-
ported by the US National Institutes of Health, the Canadian Foundation 
for AIDS Research, and the Canadian Institutes of Health Research. T. Kerr 
is supported by a Canadian Institutes of Health Research New Investigator 
award and a Michael Smith Foundation for Health Research Scholar award. 
R.S. Hogg is supported by a Michael Smith Foundation for Health Research 
Senior Scholar award.
References
1. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Sat-
ten GA, Aschman DJ, Holmberg SD, HIV Outpatient Study Investiga-
tors: Declining morbidity and mortality among patients with
advanced human immunodeficiency virus infection.  N Engl J
Med 1998, 338:853-860.
2. Hogg RS, Heath KV, Yip B, Craib KJ, O'Shaughnessy MV, Schechter
MT, Montaner JS: Improved survival among HIV-infected indi-
viduals following initiation of antiretroviral therapy.  JAMA
1998, 279:450-454.
3. Ledergerber B, Egger M, Opravil M, Telenti A, Hirschel B, Battegay M,
Vernazza P, Sudre P, Flepp M, Furrer H, Francioli P, Weber R, for the
Swiss HIV Cohort Study: Clinical progression and virological
failure on highly active antiretroviral therapy in HIV-1
patients: a prospective cohort study.  Lancet 1999, 353:863-868.
4. Hogg RS, Yip B, Chan KJ, Wood E, Craib KJ, O'Shaughnessy MV, Mon-
taner JS: Rates of disease progression by baseline CD4 cell
count and viral load after initiating triple-drug therapy.  JAMA
2001, 286:2568-2577.
5. Ickovics JR, Meade CS: Adherence to HAART among patients
with HIV: breakthroughs and barriers.  AIDS Care 2002,
14:309-318.
6. Strathdee SA, Palepu A, Cornelisse PG, Yip B, O'Shaughnessy MV,
Montaner JS, Schechter MT, Hogg RS: Barriers to use of free
antiretroviral therapy in injection drug users.  JAMA 1998,
280:547-549.
7. Wood E, Montaner JS, Bangsberg D, Tyndall MW, Strathdee SA,
O'Shaughnessy MV, Hogg RS: Expanding access to HIV antiret-
roviral therapy among marginalized populations in the
developed world.  AIDS 2003, 17:2419-2427.
8. Wood E, Montaner JS, Schechter MT, Tyndall MW, O'Shaughnessy
MV, Hogg RS: Prevalence and correlates of untreated HIV-1
infection among persons who have died in the era of modern
antiretroviral therapy.  J Infect Dis 2003, 188:1164-1170.
9. Wood E, Montaner JS, Chan K, Tyndall MW, Schechter MT, Bangs-
berg D, O'Shaughnessy MV, Hogg RS: Socioeconomic status,
access to triple therapy, and survival from HIV-disease since
1996.  AIDS 2002, 16:2065-2072.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Harm Reduction Journal 2007, 4:2 http://www.harmreductionjournal.com/content/4/1/2
Page 4 of 4
(page number not for citation purposes)
10. Wood E, Hogg RS, Bonner S, Kerr T, Li K, Palepu A, Guillemi S,
Schechter MT, Montaner JSG: Staging for antiretroviral therapy
among HIV-infected drug users.  JAMA 2004, 292:1175-1177.
11. Wood E, Hogg RS, Yip B, Harrigan PR, O'Shaughnessy MV, Montaner
JS:  Effect of medication adherence on survival of HIV-
infected adults who start highly active antiretroviral therapy
when the CD4+ cell count is 0.200 to 0.350 × 109 cells/L.  Ann
Intern Med 2003, 139:810-816.
12. Hogg RS, Yip B, Kully C, Craib KJ, O'Shaughnessy MV, Schechter MT,
Montaner JS: Improved survival among HIV-infected patients
after initiation of triple-drug antiretroviral regimens.  CMAJ
1999, 160:659-665.
13. Wood E, Montaner JS, Yip B, Tyndall MW, Schechter MT, O'Shaugh-
nessy MV, Hogg RS: Adherence and plasma HIV RNA
responses to highly active antiretroviral therapy among
HIV-1 infected injection drug users.  CMAJ 2003, 169:656-661.
14. Wainberg MA, Friedland G: Public health implications of
antiretroviral therapy and HIV drug resistance.  JAMA 1998,
279:1977-1983.
15. Bangsberg D, Tulsky JP, Hecht FM, Moss AR: Protease inhibitors
in the homeless.  JAMA 1997, 278:63-65.
16. Yeni PG, Hammer SM, Carpenter CC, Cooper DA, Fischl MA, Gatell
JM, Gazzard BG, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner
JS, Richman DD, Saag MS, Schechter M, Schooley RT, Thompson MA,
Vella S, Volberding PA: Antiretroviral treatment for adult HIV
infection in 2002: updated recommendations of the Interna-
tional AIDS Society-USA Panel.  JAMA 2002, 288:222-235.